Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Lantheus

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities across the nation. Its workforce solutions include managed services programs and recruitment process outsourcing. The firm operates through the following segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment includes travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The Physician and Leadership Solutions segment offers locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The Technology and Workforce Solutions segment consists of language interpretation, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses. The company was founded on November 10, 1997 and is headquartered in Dallas, TX.

AMN Healthcare

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics

The Ensign Group, Inc. engages in the provision of healthcare services, as well as emergency care centers and mobile ancillary businesses. It operates through the following business segments: Transitional and Skilled Services, Senior Living Services, and Home Health and Hospice Services. The company was founded by Roy E. Christensen, Christopher R. Christensen, and Gregory K. Stapley in 1999 and is headquartered in San Juan Capistrano, CA.

Ensign Group

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Merit Medical Systems

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Glaukos

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States, Americas excluding the United States, Europe, Middle East, and Africa, and Asia Pacific. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Conmed

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Prestige Consumer Healthcare

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira BioSciences

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Corcept Therapeutics

This sector includes biotechnology, pharmaceuticals, research services, retailers, hospitals, long-term-care facilities, and medical equipment. It also includes companies that provide health information services.

Healthcare

This sector includes companies that provide financial services including banks, savings and loans, asset management companies, credit services, investment brokerage firms, and insurance companies.

Financial Services

This sector includes companies engaged in the design, development, and support of computer operating systems and applications, as well as companies that make computer equipment, data storage products, networking products, semiconductors, and components.

Technology

PSCH tracks a market-cap-weighted index of small-cap health care companies taken from the S&P SmallCap 600 Index.

All investments involve risks, including the loss of principal. Performance data represents past performance and is no guarantee of future results. Investment returns and principal value will fluctuate and are subject to market volatility. Current performance may be lower or higher than the performance data quoted. Full disclosure

Invesco S&P SmallCap Health Care ETF

Why Robinhood?

About PSCH

PSCH tracks a market-cap-weighted index of small-cap health care companies taken from the S&P SmallCap 600 Index. The listed name for PSCH is Invesco Exchange-Traded Fund Trust II Invesco S&P SmallCap Health Care ETF.

What's in this fund

Sectors

Top 10 Holdings (33.26% of total assets)

PSCH Key Statistics

Average Annual Return